These slimming injections work by directly targeting adipose tissue, where they cause lipid cell destruction
That might enhance insulin sensitivity when added to lifestyle interventions
This sets up the possibility that Medicare beneficiaries could have coverage of GLP-1s for obesity under the Medicare GLP-1 Bridge in the latter half of 2026 and 2027 but then lose access in 2028 if the BALANCE Model or another coverage pathway are not implemented
Whether this fully prevents weight regain after stopping GLP-1 medication is still being studied, but the behavioral foundation Noom builds is a meaningful advantage over medication-only programs
PLoS ONE 8 , e72023 (2013)
Less common reactions associated with these medications are medullary thyroid cancer risk, severe allergic reactions, and pancreatitis. He added that, as is the case with any other medication, doctors and patients should weigh the risks against their benefits